-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Reiterates Market Outperform on Immix Biopharma, Maintains $23 Price Target

Benzinga·03/27/2026 13:33:13
Listen to the news
Citizens analyst Reni J. Benjamin reiterates Immix Biopharma (NASDAQ:IMMX) with a Market Outperform and maintains $23 price target.